Thus, these findings underscore not only the potential of using labeled acetate for cancer diagnosis and monitoring tumor growth but also highlight the possibility of targeting the MCT1‐ACSS2‐DLAT‐USP10‐c‐Myc signaling axis for cancer treatment, including enhancing the response to immune checkpoint blockade therapy. Here, SLC16A1 is linked to cancer.